Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy

被引:18
作者
Giuroiu, Iulia [1 ]
Weber, Jeffrey [1 ]
机构
[1] NYU Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
关键词
Antibody; checkpoints; costimulation; T cells; therapy; ANTI-CD40; MONOCLONAL-ANTIBODY; CD8(+) T-CELLS; METASTATIC MELANOMA PATIENTS; PHASE-I; CD28; COSTIMULATION; DACETUZUMAB SGN-40; ANTITUMOR IMMUNITY; CTLA-4; BLOCKADE; DENDRITIC CELL; CD40; ANTIBODY;
D O I
10.1097/PPO.0000000000000241
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The recent demonstration of the antitumor efficacy of checkpoint protein inhibition has resulted in the approval of blocking antibodies against the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway in multiple different histologic findings. Therapeutic successes with PD-1/PD-L1 antibodies in melanoma and lung cancer have been followed by approvals in bladder, renal, and head and neck cancers and Hodgkin lymphoma, with others undoubtedly to come. However, PD-1 is only one of many checkpoints and agonistic regulatory molecules expressed on T cells by which maintenance of the balance between costimulatory and coinhibitory signaling pathways is perturbed in cancer. The manipulation of many of these molecules in cancer patients might be associated with clinical benefit. The majority of the T-cell cosignaling receptors belong to either the immunoglobulin superfamily or the tumor necrosis factor receptor superfamily. A total of 29 immunoglobulin superfamily and 26 tumor necrosis factor receptor superfamily cosignaling receptors have been identified that are expressed on T cells, providing fertile ground for development of inhibitory or agonistic antibodies and small molecules as cancer therapeutics. In the current work, we focus on some of the most promising new checkpoints and agonistic or cosignaling molecules that are in early clinical development as single agents or in combinations with PD-1/PD-L1, cytotoxic T-lymphocyte-associated protein 4 blockade, or chemotherapy with an emphasis on those that have reached the clinic and on important targets that are in late preclinical development.
引用
收藏
页码:23 / 31
页数:9
相关论文
共 125 条
[1]   Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma [J].
Advani, Ranjana ;
Forero-Torres, Andres ;
Furman, Richard R. ;
Rosenblatt, Joseph D. ;
Younes, Anas ;
Ren, Hong ;
Harrop, Kate ;
Whiting, Nancy ;
Drachman, Jonathan G. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4371-4377
[2]  
Ansell SM, 2014, ASCO M, V32, P3024, DOI DOI 10.1200/jco.2014.32.15_suppl.3024
[3]   MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF A MURINE LIGAND FOR CD40 [J].
ARMITAGE, RJ ;
FANSLOW, WC ;
STROCKBINE, L ;
SATO, TA ;
CLIFFORD, KN ;
MACDUFF, BM ;
ANDERSON, DM ;
GIMPEL, SD ;
DAVISSMITH, T ;
MALISZEWSKI, CR ;
CLARK, EA ;
SMITH, CA ;
GRABSTEIN, KH ;
COSMAN, D ;
SPRIGGS, MK .
NATURE, 1992, 357 (6373) :80-82
[4]   Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization [J].
Baitsch, Lukas ;
Legat, Amandine ;
Barba, Leticia ;
Marraco, Silvia A. Fuertes ;
Rivals, Jean-Paul ;
Baumgaertner, Petra ;
Christiansen-Jucht, Celine ;
Bouzourene, Hanifa ;
Rimoldi, Donata ;
Pircher, Hanspeter ;
Rufer, Nathalie ;
Matter, Maurice ;
Michielin, Olivier ;
Speiser, Daniel E. .
PLOS ONE, 2012, 7 (02)
[5]   A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma [J].
Beatty, Gregory L. ;
Torigian, Drew A. ;
Chiorean, E. Gabriela ;
Saboury, Babak ;
Brothers, Alex ;
Alavi, Abass ;
Troxel, Andrea B. ;
Sun, Weijing ;
Teitelbaum, Ursina R. ;
Vonderheide, Robert H. ;
O'Dwyer, Peter J. .
CLINICAL CANCER RESEARCH, 2013, 19 (22) :6286-6295
[6]   CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans [J].
Beatty, Gregory L. ;
Chiorean, Elena G. ;
Fishman, Matthew P. ;
Saboury, Babak ;
Teitelbaum, Ursina R. ;
Sun, Weijing ;
Huhn, Richard D. ;
Song, Wenru ;
Li, Dongguang ;
Sharp, Leslie L. ;
Torigian, Drew A. ;
O'Dwyer, Peter J. ;
Vonderheide, Robert H. .
SCIENCE, 2011, 331 (6024) :1612-1616
[7]   Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors [J].
Beavis, Paul A. ;
Divisekera, Upulie ;
Paget, Christophe ;
Chow, Melvyn T. ;
John, Liza B. ;
Devaud, Christel ;
Dwyer, Karen ;
Stagg, John ;
Smyth, Mark J. ;
Darcy, Phillip K. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (36) :14711-14716
[8]   A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma [J].
Bensinger, William ;
Maziarz, Richard T. ;
Jagannath, Sundar ;
Spencer, Andrew ;
Durrant, Simon ;
Becker, Pamela S. ;
Ewald, Brett ;
Bilic, Sanela ;
Rediske, John ;
Baeck, Johan ;
Stadtmauer, Edward A. .
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 (01) :58-66
[9]   Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection [J].
Blackburn, Shawn D. ;
Shin, Haina ;
Haining, W. Nicholas ;
Zou, Tao ;
Workman, Creg J. ;
Polley, Antonio ;
Betts, Michael R. ;
Freeman, Gordon J. ;
Vignali, Dario A. A. ;
Wherry, E. John .
NATURE IMMUNOLOGY, 2009, 10 (01) :29-37
[10]  
Blay J, 1997, CANCER RES, V57, P2602